Hello, everyone, and how are you today? We are just fine, thank you. A cool breeze is wafting across the Pharmalot campus and our official mascot is, thankfully, snoozing away in a nearby corner. As for us, we are going about our usual business — brewing a cup of stimulation and foraging for interesting and saucy items. On that note, here are a few tidbits to help you get going this morning. As always, we wish you luck on your journey and, of course, please do keep in touch. …

AstraZeneca (AZN) chief executive Pascal Soriot said the company should know before the end of the year whether its experimental vaccine would protect people from Covid-19, if allowed to resume trials which were paused this week, Reuters writes. The drug maker suspended the late-stage trials after an illness in a study subject in the U.K. The patient was reportedly suffering from neurological symptoms associated with a rare spinal inflammatory disorder called transverse myelitis.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy